Fulcrum Therapeutics
Clinical trials sponsored by Fulcrum Therapeutics, explained in plain language.
-
Drug trial aims to halt debilitating muscle loss
Disease control TerminatedThis study tested whether a pill called losmapimod could slow the progression of facioscapulohumeral muscular dystrophy (FSHD), a genetic disease that causes progressive muscle weakness. About 260 adults with FSHD took either the drug or a placebo pill twice daily for 48 weeks to…
Phase: PHASE3 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Apr 04, 2026 03:50 UTC
-
Pilot drug trial seeks to slow Muscle-Wasting disease
Disease control TerminatedThis study tested an oral drug called losmapimod in adults with FSHD1, a genetic muscle-wasting disease. The main goal was to check the drug's safety and see if it reached and affected the muscles over about a year of treatment. Researchers measured drug levels and specific prote…
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
Extended drug trial seeks to tame debilitating muscle disease
Disease control TerminatedThis study aimed to check the long-term safety of a drug called losmapimod for adults with facioscapulohumeral muscular dystrophy (FSHD), a condition that weakens muscles. It was an extension of a previous trial, allowing participants to continue taking the drug. The main goal wa…
Phase: PHASE2 • Sponsor: Fulcrum Therapeutics • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC